The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Antimicrobial peptides under clinical investigation
Abstract
Overuse of conventional antibiotics as well as the slow pace of new antibiotic drug development leads to antimicrobial resistance (AMR). Because infections with multi‐drug resistant (MDR) pathogens have become a public health issue, the need for a novel class of antibiotics is urgent. Recently, antimicrobial peptides (AMPs) have emerged as a promising platform to fight against MDR bacteria ensuring broad‐spectrum antimicrobial activity and relatively low resistance emergence. Currently, a number of AMPs are undergoing clinical and preclinical trials against various infectious diseases. This review lists the 36 AMPs (27 clinical and 9 preclinical) with brief information about their origin, structure, mechanism, and development status. From the examples of AMPs under clinical investigation, we categorized several improvement strategies and highlighted directions for the future design of AMPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Here, the binding of cationic and amphipathic AMP to negatively charged membranes, followed by membrane rearrangements and pore formation, lead to bacterial inactivation.4,6”
From Self-Assembly Pathways and Antimicrobial Properties of Lysozyme in Different Aggregation States (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies
Hancock, R. E. W., & Sahl, H.-G. (2006) · Nature Biotechnology · doi:10.1038/nbt1267 · Cited by 4,208
Antimicrobial resistance: a global multifaceted phenomenon
Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015) · Pathogens and Global Health · doi:10.1179/2047773215y.0000000030 · Cited by 3,296
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
The crisis in antibiotic resistance
Neu, H. C. (1992) · Science · doi:10.1126/science.257.5073.1064 · Cited by 2,834
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Zasloff, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5449 · Cited by 2,305
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Cited by
Antimicrobial peptides: Application informed by evolution
Lazzaro, B. P., Zasloff, M., & Rolff, J. (2020) · Science · doi:10.1126/science.aau5480 · Cited by 1,069
Mechanism of Antimicrobial Peptides: Antimicrobial, Anti-Inflammatory and Antibiofilm Activities
Luo, Y., & Song, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111401 · Cited by 559
Gan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields
Moretta, A., Scieuzo, C., Petrone, A. M., Salvia, R., Manniello, M. D., Franco, A., Lucchetti, D., Vassallo, A., Vogel, H., Sgambato, A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.668632 · Cited by 497
Antimicrobial peptides as therapeutic agents: opportunities and challenges
Mahlapuu, M., Björn, C., & Ekblom, J. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1796576 · Cited by 484
The oralome and its dysbiosis: New insights into oral microbiome-host interactions
Radaic, A., & Kapila, Y. L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.02.010 · Cited by 467
Antimicrobial peptides (AMPs): A promising class of antimicrobial compounds
Erdem Büyükkiraz, M., & Kesmen, Z. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15314 · Cited by 454
Greco, I., Molchanova, N., Holmedal, E., Jenssen, H., Hummel, B. D., Watts, J. L., Håkansson, J., Hansen, P. R., & Svenson, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-69995-9 · Cited by 441
Chemically modified and conjugated antimicrobial peptides against superbugs
Li, W., Separovic, F., O'Brien-Simpson, N. M., & Wade, J. D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01026j · Cited by 439
Thapa, R. K., Diep, D. B., & Tønnesen, H. H. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.025 · Cited by 378
Mode-of-Action of Antimicrobial Peptides: Membrane Disruption vs. Intracellular Mechanisms
Benfield, A. H., & Henriques, S. T. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.610997 · Cited by 367
Design, optimization, and nanotechnology of antimicrobial peptides: From exploration to applications
Tan, P., Fu, H., & Ma, X. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101229 · Cited by 351
Antimicrobial Peptides: A Potent Alternative to Antibiotics
Rima, M., Rima, M., Fajloun, Z., Sabatier, J.-M., Bechinger, B., & Naas, T. (2021) · Antibiotics · doi:10.3390/antibiotics10091095 · Cited by 350
Antimicrobial peptides: new hope in the war against multidrug resistance
Mwangi, J., Hao, X., Lai, R., & Zhang, Z.-Y. (2019) · Zool. Res. · doi:10.24272/j.issn.2095-8137.2019.062 · Cited by 289
Antimicrobial peptides towards clinical application: Delivery and formulation
Wang, C., Hong, T., Cui, P., Wang, J., & Xia, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.028 · Cited by 281
Antibiofilm activity of host defence peptides: complexity provides opportunities
Hancock, R. E. W., Alford, M. A., & Haney, E. F. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00585-w · Cited by 270
Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation
Jiang, Y., Chen, Y., Song, Z., Tan, Z., & Cheng, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.016 · Cited by 267
Antifungal Peptides as Therapeutic Agents
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00105 · Cited by 264
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Self-Assembly Pathways and Antimicrobial Properties of Lysozyme in Different Aggregation States
Kummer, N., Wu, T., De France, K. J., Zuber, F., Ren, Q., Fischer, P., Campioni, S., & Nyström, G. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00870 · Cited by 46
Mining the UniProtKB /Swiss‐Prot database for antimicrobial peptides
Li, C., Sutherland, D., Salehi, A., Richter, A., Lin, D., Aninta, S. I., Ebrahimikondori, H., Yanai, A., Coombe, L., Warren, R. L., et al. (2025) · Protein Science · doi:10.1002/pro.70083 · Cited by 9
Ngan, H. D., Huy, B. L., Uyen, C. L., Phuong, H. B. T., & Xuan, H. L. (2025) · European Food Research and Technology · doi:10.1007/s00217-025-04754-6 · Cited by 3
Metadata
- Authors
- Koo, H. B., & Seo, J.
- Venue
- Peptide Science
- Publisher
- Wiley
- Published
- 2019-06-03
- Volume
- 111
- Issue
- 5
- ISSN
- 2475-8817 (ISSN-L)
- OpenAlex
- W2948285055
- Cited by
- 376
- References
- 95
- FWCI
- 29.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.